journal证据等级 B独立来源
证据页CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Blood (Chong EA et al.), 134(21):1873–1875
发布 2019年9月25日访问于 2026年9月19日更新 2026年9月20日
原始来源
https://pmc.ncbi.nlm.nih.gov/articles/PMC6872962/
pmc.ncbi.nlm.nih.gov
核验
| 核验 | 独立于主体的来源 |
| 证据等级 | B · 同行评审·专业机构 |
| 独立来源 | 与对象无关的独立来源 |
| 来源 | journal |
| 链接状态 | 最近检查时可访问 |
官方声明是服务方的陈述,除非另有标注,否则未经 worldwiki 验证。 来源政策
引用页面 (8)
FactCell Viability: CAR T (CTL019) viability release specification = At least 80% for the commercial product; early clinical trials used at least 70% %FactCell Viability: Viability and clinical outcome (CAR T) = No link was found between product viability below 80% and response, expansion or survival in 123 pediatric ALL and 25 adult DLBCL patientsAnswerHow is cell viability percentage calculated?AnswerWhat is an acceptable cell viability for cell therapy products?AnswerTrypan blue vs MTT: which cell viability assay should I use?AnswerWhy does cell viability drop after thawing cryopreserved cells?AnswerDoes higher cell viability mean better fat graft survival?ArticleCell Viability: Definition, Assays, Acceptance Criteria and Limits of Interpretation